Ms. Giroud was the founder and CEO of D-TARGET, a leading clinical research organization specializing in medical device clinical trials throughout the European continent.

Having joined the Premier Research team in July 2007 with the acquisition of D-TARGET, Ms. Giroud ensured the transition period in the capacity of VP global strategic development for medical devices until February 2008.

Prior to founding D-TARGET, Ms. Giroud has been responsible for the successful development and implementation of worldwide clinical research as Director of Clinical Affairs for Collagen Inc.

At Medinvent, she handled Trial Management and Product Manager responsibilities for the product "Wallstent", known as the very first vascular stent in the world to be placed on the market and now considered one of the major cardiovascular products.

As a Medical Research Associate in the corporate infertility department for Ares Serono, she coordinated multiple worldwide investigations, significantly contributing to Serono's placement of the world's first recombinant hormone for the treatment of female and male infertility on the market.

A highly coveted international speaker, Ms. Giroud is also an active member of the ISO 14155 task force for the "Clinical investigations for medical devices and clinical investigation plan" and serves as a liaison with the Competent Authority medical device working group.

For more information, please contact:

Danielle Giroud